<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Forum Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Open Forum Infect Dis</journal-id><journal-id journal-id-type="publisher-id">ofid</journal-id><journal-title-group><journal-title>Open Forum Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2328-8957</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5630951</article-id><article-id pub-id-type="doi">10.1093/ofid/ofx163.1279</article-id><article-id pub-id-type="publisher-id">ofx163.1279</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Poster Abstract</subject></subj-group></subj-group></article-categories><title-group><article-title>Impact of an Antimicroibal Stewardship Bundle of Rapid Identification of Methicillin Susceptibility and Active Intervention on Treatment of <italic>Staphylococcus aureus</italic> Bacteremia</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Karkow</surname><given-names>Diana</given-names></name><degrees>PharmD</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Ford</surname><given-names>Bradley</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Hoff</surname><given-names>Brian</given-names></name><degrees>PharmD</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Ernst</surname><given-names>Erika</given-names></name><degrees>PharmD</degrees><xref ref-type="aff" rid="AF0004">4</xref></contrib></contrib-group><aff id="AF0001">
<label>1</label>
<institution>Department Pharmaceutical Care, University of Iowa Hospitals and Clinics</institution>, <addr-line>Iowa City, Iowa</addr-line></aff><aff id="AF0002">
<label>2</label>
<institution>Pathology, University of Iowa</institution>, <addr-line>Iowa City, Iowa</addr-line></aff><aff id="AF0003">
<label>3</label>
<institution>Department of Pharmacy, University of Iowa Hospitals and Clinics</institution>, <addr-line>Iowa City, Iowa</addr-line></aff><aff id="AF0004">
<label>4</label>
<institution>Division of Health Services Research, Department of Pharmacy Practice and Science, University of Iowa, College of Pharmacy</institution>, <addr-line>Iowa City, Iowa</addr-line></aff><author-notes><fn id="fn-0001"><p>
<bold>Session:</bold> 168. Stewardship: Improving Outcomes</p><p>
<italic>Friday, October 6, 2017: 12:30 PM</italic>
</p></fn></author-notes><pub-date pub-type="collection"><season>Fall</season><year>2017</year></pub-date><pub-date pub-type="epub" iso-8601-date="2017-10-04"><day>04</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>04</day><month>10</month><year>2017</year></pub-date><volume>4</volume><issue>Suppl 1</issue><issue-title>ID Week 2017 Abstracts</issue-title><fpage>S495</fpage><lpage>S495</lpage><permissions><copyright-statement>© The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</copyright-statement><copyright-year>2017</copyright-year><license license-type="cc-by-nc-nd" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xlink:href="ofx163.1279.pdf"></self-uri><abstract><title><offsets xml_i="4279" xml_f="4287" txt_i="11" txt_f="19">Abstract</offsets></title><sec id="s1"><title><offsets xml_i="4315" xml_f="4325" txt_i="20" txt_f="30">Background</offsets></title><p><offsets xml_i="4336" xml_f="4337" txt_i="31" txt_f="32">
</offsets><italic><offsets xml_i="4345" xml_f="4366" txt_i="32" txt_f="53">Staphylococcus aureus</offsets></italic><offsets xml_i="4375" xml_f="4587" txt_i="53" txt_f="265">bacteremia (SAB) is a major source of morbidity and mortality. Studies show rapid initiation of appropriate antibiotic therapy is essential to treatment and optimal therapy depends upon antibiotic susceptibility.</offsets></p></sec><sec id="s2"><title><offsets xml_i="4617" xml_f="4624" txt_i="267" txt_f="274">Methods</offsets></title><p><offsets xml_i="4635" xml_f="5941" txt_i="275" txt_f="1581">Using a quasi-experimental pre-post intervention study we evaluated a bundled antimicrobial stewardship rapid identification and susceptibility testing protocol. The pre-intervention group included all patients treated for SAB at our hospital between April and Sept 2015; the post-intervention group was between April and Sept 2016. We implemented combined rapid identification by MALDI-TOF with a modified immunochromatographic assay for penicillin–binding protein 2a to differentiate MSSA and MRSA. Identification and susceptibility results were communicated to the primary team per usual protocol and to an antimicrobial stewardship pharmacist for intervention. The primary outcome was time to optimal antibiotic therapy calculated as the difference in time from the first dose of antibiotic therapy to the discontinuation time of the non-optimal antibiotic, for patients receiving combination therapy or first dose of optimal therapy, determined using a predefined protocol developed in collaboration with the Infectious Diseases (ID) consult service. Additional outcomes included time to pathogen identification, time to ID consult, time to source control, length of hospital stay (LOS), intensive care unit LOS, inpatient-days of therapy, and in-hospital mortality. Outcomes were compared using the χ</offsets><sup><offsets xml_i="5946" xml_f="5947" txt_i="1581" txt_f="1582">2</offsets></sup><offsets xml_i="5953" xml_f="5973" txt_i="1582" txt_f="1602"> test, or Student’s </offsets><italic><offsets xml_i="5981" xml_f="5987" txt_i="1602" txt_f="1608">t-test</offsets></italic><offsets xml_i="5996" xml_f="6021" txt_i="1608" txt_f="1633"> for independent samples.</offsets></p></sec><sec id="s3"><title><offsets xml_i="6051" xml_f="6058" txt_i="1635" txt_f="1642">Results</offsets></title><p><offsets xml_i="6069" xml_f="6197" txt_i="1643" txt_f="1771">74 pre-intervention and 55 post-intervention patients were included. Time in days to optimal therapy (1.7 ± 1.2 vs.. 2.5 ± 1.6, </offsets><italic><offsets xml_i="6205" xml_f="6208" txt_i="1771" txt_f="1774">P =</offsets></italic><offsets xml_i="6217" xml_f="6291" txt_i="1774" txt_f="1848"> 0.003), total time to pathogen identification (1.5 ± 0.5 vs.. 2.7 ± 0.6, </offsets><italic><offsets xml_i="6299" xml_f="6305" txt_i="1848" txt_f="1851">P &lt;</offsets></italic><offsets xml_i="6314" xml_f="6372" txt_i="1851" txt_f="1909"> 0.001) and time to ID consult (1.6 ± 1.5 vs.. 2.8 ± 2.4, </offsets><italic><offsets xml_i="6380" xml_f="6383" txt_i="1909" txt_f="1912">P =</offsets></italic><offsets xml_i="6392" xml_f="6539" txt_i="1912" txt_f="2056"> &lt;0.001) were significantly shorter in the intervention group. All other outcomes were not statistically significantly different between groups.</offsets></p></sec><sec id="s4"><title><offsets xml_i="6569" xml_f="6579" txt_i="2058" txt_f="2068">Conclusion</offsets></title><p><offsets xml_i="6590" xml_f="6827" txt_i="2069" txt_f="2306">We demonstrate significant improvement in time to pathogen identification, optimal therapy, and ID consult utilizing rapid pathogen identification and susceptibility testing coupled with antimicrobial stewardship pharmacist intervention.</offsets></p></sec><sec id="s5"><title><offsets xml_i="6857" xml_f="6868" txt_i="2308" txt_f="2319">Disclosures</offsets></title><p><offsets xml_i="6879" xml_f="6880" txt_i="2320" txt_f="2321">
</offsets><bold><offsets xml_i="6886" xml_f="6894" txt_i="2321" txt_f="2329">E. Ernst</offsets></bold><offsets xml_i="6901" xml_f="6953" txt_i="2329" txt_f="2381">, Merck Sharp and Dohme: Consultant, Consulting fee.</offsets></p></sec></abstract><counts><page-count count="1"></page-count></counts></article-meta></front></article>